CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS
Fluorine is a key element in drug design due to its ability to enhance metabolic stability, binding affinity, and bioavailability. Fluorine’s properties lead to more stable drugs with longer half-lives, reducing dosing frequency and improving patient compliance. Its small size and high electronegati...
Збережено в:
| Дата: | 2025 |
|---|---|
| Автори: | , , , , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
V.I.Vernadsky Institute of General and Inorganic Chemistry
2025
|
| Онлайн доступ: | https://ucj.org.ua/index.php/journal/article/view/710 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Ukrainian Chemistry Journal |
Репозитарії
Ukrainian Chemistry Journal| id |
oai:ojs2.1444248.nisspano.web.hosting-test.net:article-710 |
|---|---|
| record_format |
ojs |
| spelling |
oai:ojs2.1444248.nisspano.web.hosting-test.net:article-7102025-04-28T12:40:53Z CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS Han, Jianlin Wzorek, Alicja Dhawan, Gagan Zhang, Wei Sorochinsky, Alexander Baecker, Daniel Ono, Taizo Klika, Karel Soloshonok, Vadim Fluorine, chirality, drug design, pharmaceuticals, self-disproportionation of enantiomers, bioactivity. Fluorine is a key element in drug design due to its ability to enhance metabolic stability, binding affinity, and bioavailability. Fluorine’s properties lead to more stable drugs with longer half-lives, reducing dosing frequency and improving patient compliance. Its small size and high electronegativity also improve binding affinity, resulting in more effective treatments with lower doses. For example, fluorine increases a compound’s ability to cross cell membranes. This article highlights advancements in chiral, fluorine-containing pharmaceuticals introduced over the past five years, focusing on their synthesis, therapeutic benefits, mechanisms of action, and the impact of fluorine on efficacy and safety. Chiral molecules, essential in drug development, exist in two enantiomeric forms with distinct biological activities. Synthesizing chiral, fluorine-containing drugs involves techniques like asymmetric synthesis to produce pure enantiomers, resulting in drugs with increased potency, selectivity, and reduced side effects. Understanding their mechanisms of action provides valuable insights into efficacy and safety. Reviewing recently FDA-approved chiral drugs offers insights into fluorine chemistry in drug development and future therapeutic innovations. Recent FDA approvals highlight the significance of chiral, fluorine-containing drugs in various therapeutic areas, enabling targeted and effective treatments. Analyzing these approvals reveals trends shaping drug development’s future. The article also addresses the need for more research into self-disproportionation of enantiomers (SDE) in chiral, fluorinated compounds and concerns about excessive fluorine levels. SDE can affect pharmaceutical product purity. Research into SDE in fluorinated compounds ensures drug quality. Additionally, fluorine’s widespread use raises environmental and health concerns, necessitating studies on long-term effects and mitigation strategies. V.I.Vernadsky Institute of General and Inorganic Chemistry 2025-03-25 Article Article Organic chemistry Органическая xимия Органічна xімія application/pdf https://ucj.org.ua/index.php/journal/article/view/710 10.33609/2708-129X.91.2.2025.55-90 Ukrainian Chemistry Journal; Vol. 91 No. 2 (2025): Ukrainian Chemistry Journal; 55-90 Украинский химический журнал; Том 91 № 2 (2025): Ukrainian Chemistry Journal; 55-90 Український хімічний журнал; Том 91 № 2 (2025): Ukrainian Chemistry Journal; 55-90 2708-129X 2708-1281 en https://ucj.org.ua/index.php/journal/article/view/710/359 |
| institution |
Ukrainian Chemistry Journal |
| baseUrl_str |
|
| datestamp_date |
2025-04-28T12:40:53Z |
| collection |
OJS |
| language |
English |
| topic_facet |
Fluorine chirality drug design pharmaceuticals self-disproportionation of enantiomers bioactivity. |
| format |
Article |
| author |
Han, Jianlin Wzorek, Alicja Dhawan, Gagan Zhang, Wei Sorochinsky, Alexander Baecker, Daniel Ono, Taizo Klika, Karel Soloshonok, Vadim |
| spellingShingle |
Han, Jianlin Wzorek, Alicja Dhawan, Gagan Zhang, Wei Sorochinsky, Alexander Baecker, Daniel Ono, Taizo Klika, Karel Soloshonok, Vadim CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS |
| author_facet |
Han, Jianlin Wzorek, Alicja Dhawan, Gagan Zhang, Wei Sorochinsky, Alexander Baecker, Daniel Ono, Taizo Klika, Karel Soloshonok, Vadim |
| author_sort |
Han, Jianlin |
| title |
CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS |
| title_short |
CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS |
| title_full |
CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS |
| title_fullStr |
CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS |
| title_full_unstemmed |
CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS |
| title_sort |
chiral, fluorine-containing pharmaceuticals |
| description |
Fluorine is a key element in drug design due to its ability to enhance metabolic stability, binding affinity, and bioavailability. Fluorine’s properties lead to more stable drugs with longer half-lives, reducing dosing frequency and improving patient compliance. Its small size and high electronegativity also improve binding affinity, resulting in more effective treatments with lower doses. For example, fluorine increases a compound’s ability to cross cell membranes. This article highlights advancements in chiral, fluorine-containing pharmaceuticals introduced over the past five years, focusing on their synthesis, therapeutic benefits, mechanisms of action, and the impact of fluorine on efficacy and safety. Chiral molecules, essential in drug development, exist in two enantiomeric forms with distinct biological activities. Synthesizing chiral, fluorine-containing drugs involves techniques like asymmetric synthesis to produce pure enantiomers, resulting in drugs with increased potency, selectivity, and reduced side effects. Understanding their mechanisms of action provides valuable insights into efficacy and safety. Reviewing recently FDA-approved chiral drugs offers insights into fluorine chemistry in drug development and future therapeutic innovations. Recent FDA approvals highlight the significance of chiral, fluorine-containing drugs in various therapeutic areas, enabling targeted and effective treatments. Analyzing these approvals reveals trends shaping drug development’s future. The article also addresses the need for more research into self-disproportionation of enantiomers (SDE) in chiral, fluorinated compounds and concerns about excessive fluorine levels. SDE can affect pharmaceutical product purity. Research into SDE in fluorinated compounds ensures drug quality. Additionally, fluorine’s widespread use raises environmental and health concerns, necessitating studies on long-term effects and mitigation strategies. |
| publisher |
V.I.Vernadsky Institute of General and Inorganic Chemistry |
| publishDate |
2025 |
| url |
https://ucj.org.ua/index.php/journal/article/view/710 |
| work_keys_str_mv |
AT hanjianlin chiralfluorinecontainingpharmaceuticals AT wzorekalicja chiralfluorinecontainingpharmaceuticals AT dhawangagan chiralfluorinecontainingpharmaceuticals AT zhangwei chiralfluorinecontainingpharmaceuticals AT sorochinskyalexander chiralfluorinecontainingpharmaceuticals AT baeckerdaniel chiralfluorinecontainingpharmaceuticals AT onotaizo chiralfluorinecontainingpharmaceuticals AT klikakarel chiralfluorinecontainingpharmaceuticals AT soloshonokvadim chiralfluorinecontainingpharmaceuticals |
| first_indexed |
2025-09-24T17:44:00Z |
| last_indexed |
2025-09-24T17:44:00Z |
| _version_ |
1849658135924441088 |